DuPont Implements Chemical Information Management System DeltaSoft's ChemCart
News Feb 22, 2008
DeltaSoft, Inc. has announced that DuPont Central Research & Development has implemented its ChemCart based chemical information management system to enhance their research efforts.
ChemCart products provide a web-based, configurable forms interface to chemistry and other research data. As part of the multi-year, global license agreement, DeltaSoft has extended ChemCart functionality to support workflows related to handling complex multi-component chemical samples. The system is now being used by scientists and registration specialists at DuPont to track chemical research materials and their associated properties.
"The flexible forms interface of ChemCart allows us to provide tailored applications to the highly diverse research teams within DuPont," said Mark Andrews of DuPont Central Research & Development. "The system will allow us to create a central repository for research data so we can more easily query, update, and securely share information across the company."
"Working together with the DuPont team, we have been able to quickly deploy a solution that provides a powerful set of features to both research scientists and information technology teams", said Michael Dippolito, President of DeltaSoft. "We are pleased that DuPont has selected DeltaSoft's ChemCart product and look forward to a continued partnership."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE